New hope for polycythemia vera patients who Can't use standard drugs

NCT ID NCT04182100

Completed Disease control Sponsor: PharmaEssentia Japan K.K. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 2 study tested a drug called P1101 (ropeginterferon alfa-2b) in 29 Japanese adults with polycythemia vera (PV), a blood disorder that causes too many red blood cells. The participants were people for whom standard treatments are hard to use, such as younger patients or those with certain symptoms. The goal was to see if P1101 could control blood counts without needing phlebotomy (blood removal). The drug was injected under the skin every two weeks, with doses adjusted over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: P1101 (ropeginterferon alfa-2b)
What this could lead to: If successful, P1101 could offer a new treatment option for polycythemia vera patients who cannot tolerate or do not respond to current standard therapies.
What could go wrong: This is a small, single-arm Phase 2 trial with only 29 patients, so results may not apply broadly. The drug may cause side effects like flu-like symptoms, and long-term safety is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA (PV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera Myeloproliferative Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLYCYTHEMIA VERA (PV)

Contacts and locations

Locations

Ehime University Hospital

Toon-shi, Ehime, 791-0295, Japan
Juntendo University Hospital

Bunkyo-ku, Tokyo, 113-8431, Japan
Keio University Hospital

Shinjuku-ku, Tokyo, 160-8582, Japan
Mie University Hospital

Tsu, Mie-ken, Japan
NTT Medical Center Tokyo

Shinagawa-ku, Tokyo, 141-8625, Japan
Osaka University Hospital

Suita-shi, Osaka, 565-0871, Japan
Tokyo Medical University Hospital

Shinjuku-ku, Tokyo, 160-0023, Japan
University of Yamanashi Hospital

Chuo-shi, Yamanashi, 409-3898, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.